Baseline and Longitudinal Ioflupane SPECT Findings in DLB and MCI‐LB. (20th December 2022)

• Record Type: Journal Article
• Authors: Boeve, Bradley F.; Miyagawa, Toji; Przybelski, Scott A.; Min, Paul H; Jordan, Lennon; Lesnick, Tim; Savica, Rodolfo; Graff‐Radford, Jonathan; Jones, David T.; Botha, Hugo; Ramanan, Vijay K; Knopman, David S.; Petersen, Ronald C.; Graff‐Radford, Neill R.; Day, Gregory S; Fields, Julie A.; Machulda, Mary M.; Ferman, Tanis J; Forsberg, Leah K.; Diaz‐Galvan, Patricia; Li, Wentao; Christine, Cliatt Brown J; Jack, Clifford R.; Jain, Manoj K.; Kantarci, Kejal; Lowe, Val J.
• Is Part Of: Alzheimer's & dementia. Volume 18(2022)Supplement 5
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-12-20
• Subjects: Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1002/alz.067066
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Background: Reduced striatal uptake on ioflupane SPECT is considered an indicative biomarker for Dementia with Lewy Bodies (DLB), and has been proposed as an indicative biomarker for Mild Cognitive Impairment with Lewy Bodies (MCI‐LB). Little data exists on the profile of uptake on key striatal regions of interest (ROIs) in DLB or MCI‐LB. Method: Participants with DLB or MCI‐LB at baseline based on the presence of ≥2 core clinical DLB features, and ≥2 ioflupane SPECT scans performed approximately annually, were identified from the Mayo ADRC database. Minimum brain laterality z‐score values for the putamen (whole, anterior and posterior), caudate and striatum were determined using DaTQUANT 2 software. Baseline clinical and scan data was used for all analyses, and the annualized minimum putamen z‐change was determined on serial scans. The scan was considered abnormal if the minimum putamen z‐score was <‐0.98 based on clinicopathologic data. Result: 27 participants were included (21 DLB and 6 MCI‐LB, 96% male). Compared to MCI‐LB, DLB had a lower mean MoCA score and a trend toward a higher UPDRS score compared to MCI‐LB; there were no statistically significant differences in age, sex, onset age or duration of cognitive decline, or presence of other core DLB features. The majority (89%) had an abnormal scan at baseline. All ROI z‐scores showed the expected general trend of DLB<MCI‐LB, and the annualized z‐change was more negative in DLB, but none of the findings reached statistical significance. Conclusion: These findings suggest in MCI‐LB and DLB that 1) an abnormal ioflupane SPECT scan is frequently present at diagnosis, 2) z‐scores become more negative over time, and 3) the annualized z‐change is similar. Similar findings in larger cohorts would support the use of ioflupane SPECT as a biomarker in both MCI‐LB and DLB clinical trials.